SYRA vs. BACK, CHRO, XBIO, ADXS, KZIA, IONM, IBIO, CELZ, HOTH, and SONN
Should you be buying Syra Health stock or one of its competitors? The main competitors of Syra Health include IMAC (BACK), Chromocell Therapeutics (CHRO), Xenetic Biosciences (XBIO), Ayala Pharmaceuticals (ADXS), Kazia Therapeutics (KZIA), Assure (IONM), iBio (IBIO), Creative Medical Technology (CELZ), Hoth Therapeutics (HOTH), and Sonnet BioTherapeutics (SONN). These companies are all part of the "medical" sector.
IMAC (NASDAQ:BACK) and Syra Health (NASDAQ:SYRA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking.
In the previous week, IMAC had 55 more articles in the media than Syra Health. MarketBeat recorded 58 mentions for IMAC and 3 mentions for Syra Health. Syra Health's average media sentiment score of 0.14 beat IMAC's score of -0.59 indicating that IMAC is being referred to more favorably in the media.
Syra Health has lower revenue, but higher earnings than IMAC.
5.8% of IMAC shares are owned by institutional investors. Comparatively, 4.8% of Syra Health shares are owned by institutional investors. 10.0% of IMAC shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Syra Health has a net margin of 0.00% compared to Syra Health's net margin of -176.22%. IMAC's return on equity of 0.00% beat Syra Health's return on equity.
IMAC and Syra Health both received 0 outperform votes by MarketBeat users.
Summary
IMAC and Syra Health tied by winning 5 of the 10 factors compared between the two stocks.
Get Syra Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syra Health Competitors List
Related Companies and Tools
